In all patients with metastatic prostate cancer, after the initial diagnosis, physicians often begin androgen blockade therapy, which means either surgical removal of both testes or pharmacological debridement with drugs such as Norelide and Inhibiton. Often, this therapy will have a relatively satisfactory clinical effect at the beginning, as the patient’s serum PSA level drops linearly and self-perception improves significantly. However, with the prolongation of treatment, there is a gradual rise in PSA levels, accompanied by the re-emergence of tumor symptoms, an increase in metastases, and so on. At this point, prostate cancer enters a stage that is medically known as “destructive resistant prostate cancer”. Once this stage is reached, if no other measures are taken, the tumor tends to progress rapidly and the expected survival is very short.